Joseph Coyle

List of Publications by Year in Descending Order

315 papers	37,864 citations	86 h-index	190 g-index
343 ext. papers	40,269 ext. citations	7.8 avg, IF	7.39 L-index

#	Paper	IF	Citations
315	Altered neural oscillations and behavior in a genetic mouse model of NMDA receptor hypofunction. *Scientific Reports*, **2021**, 11, 9031	4.9	6
314	Dopaminergic neuromodulation of prefrontal cortex activity requires the NMDA receptor coagonist d-serine. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	3
313	Factors regulating serine racemase and d-amino acid oxidase expression in the mouse striatum. *Brain Research*, **2021**, 1751, 147202	3.7	2
312	Utilizing public health data to geotarget hepatitis C virus elimination approaches in urban and rural Michigan. *Journal of Viral Hepatitis*, **2021**, 28, 440-444	3.4	0
311	D-Serine, the Shape-Shifting NMDA Receptor Co-agonist. *Neurochemical Research*, **2020**, 45, 1344-1353	4.6	13
310	Electroretinographic Abnormalities and Sex Differences Detected with Mesopic Adaptation in a Mouse Model of Schizophrenia: A and B Wave Analysis **2020**, 61, 16		3
309	Postsynaptic Serine Racemase Regulates NMDA Receptor Function. *Journal of Neuroscience*, **2020**, 40, 9564-9575	6.6	14
308	Serine Racemase Expression by Striatal Neurons. *Cellular and Molecular Neurobiology*, **2020**, 1	4.6	5
307	The Discovery and Characterization of Targeted Perikaryal-Specific Brain Lesions With Excitotoxins. *Frontiers in Neuroscience*, **2020**, 14, 927	5.1	0
306	Activated microglia cause metabolic disruptions in developmental cortical interneurons that persist in interneurons from individuals with schizophrenia. *Nature Neuroscience*, **2020**, 23, 1352-1364	25.5	14
305	Fifty Years of Research on Schizophrenia: The Ascendance of the Glutamatergic Synapse. *American Journal of Psychiatry*, **2020**, 177, 1119-1128	11.9	14
304	iPSC-derived homogeneous populations of developing schizophrenia cortical interneurons have compromised mitochondrial function. *Molecular Psychiatry*, **2020**, 25, 2873-2888	15.1	25
303	Dysregulated protocadherin-pathway activity as an intrinsic defect in induced pluripotent stem cell-derived cortical interneurons from subjects with schizophrenia. *Nature Neuroscience*, **2019**, 22, 229-242	25.5	50
302	Investigating brain d-serine: Advocacy for good practices. *Acta Physiologica*, **2019**, 226, e13257	5.6	16
301	Glutamate hypothesis in schizophrenia. *Psychiatry and Clinical Neurosciences*, **2019**, 73, 204-215	6.2	117
300	Neurotoxic astrocytes express the d-serine synthesizing enzyme, serine racemase, in Alzheimer's disease. *Neurobiology of Disease*, **2019**, 130, 104511	7.5	26
299	Targeted Treatment of Individuals With Psychosis Carrying a Copy Number Variant Containing a Genomic Triplication of the Glycine Decarboxylase Gene. *Biological Psychiatry*, **2019**, 86, 523-535	7.9	21

298	Hepatitis C transmission in young people who inject drugs: Insights using a dynamic model informed by state public health surveillance. *Epidemics*, **2019**, 27, 86-95	5.1	9
297	N-Methyl-d-aspartate receptor co-agonist availability affects behavioral and neurochemical responses to cocaine: insights into comorbid schizophrenia and substance abuse. *Addiction Biology*, **2019**, 24, 40-50	4.6	10
296	Astrocytes in primary cultures express serine racemase, synthesize d-serine and acquire A1 reactive astrocyte features. *Biochemical Pharmacology*, **2018**, 151, 245-251	6	28
295	Location matters: distinct DNA methylation patterns in GABAergic interneuronal populations from separate microcircuits within the human hippocampus. *Human Molecular Genetics*, **2018**, 27, 254-265	5.6	5
294	Serine Racemase and D-serine in the Amygdala Are Dynamically Involved in Fear Learning. *Biological Psychiatry*, **2018**, 83, 273-283	7.9	17
293	In Vivo Brain Glycine and Glutamate Concentrations in Patients With First-Episode Psychosis Measured by Echo Time-Averaged Proton Magnetic Resonance Spectroscopy at 4T. *Biological Psychiatry*, **2018**, 83, 484-491	7.9	22
292	3.2 PARVALBUMIN INTERNEURON IMPAIRMENT INDUCED BY OXIDATIVE STRESS AS A COMMON PATHOLOGICAL MECHANISM IN ANIMAL MODELS OF SCHIZOPHRENIA. *Schizophrenia Bulletin*, **2018**, 44, S1-S2	1.3	78
291	Altered CREB Binding to Activity-Dependent Genes in Serine Racemase Deficient Mice, a Mouse Model of Schizophrenia. *ACS Chemical Neuroscience*, **2018**, 9, 2205-2209	5.7	2
290	Dysbindin-1 contributes to prefrontal cortical dendritic arbor pathology in schizophrenia. *Schizophrenia Research*, **2018**, 201, 270-277	3.6	11
289	The Role of Serine Racemase in the Pathophysiology of Brain Disorders. *Advances in Pharmacology*, **2018**, 82, 35-56	5.7	30
288	Probing the lithium-response pathway in hiPSCs implicates the phosphoregulatory set-point for a cytoskeletal modulator in bipolar pathogenesis. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E4462-E4471	11.5	93
287	Oxidative stress-driven parvalbumin interneuron impairment as a common mechanism in models of schizophrenia. *Molecular Psychiatry*, **2017**, 22, 936-943	15.1	187
286	Astroglial Versus Neuronal D-Serine: Check Your Controls!. *Trends in Neurosciences*, **2017**, 40, 520-522	13.3	33
285	Schizophrenia: Basic and Clinical. *Advances in Neurobiology*, **2017**, 15, 255-280	2.1	19
284	Modeling schizophrenia pathogenesis using patient-derived induced pluripotent stem cells (iPSCs). *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2017**, 1863, 2382-2387	6.9	10
283	SU93. Targeted Treatment of a Genetic Mutation in Glycine Decarboxylase With d-Cycloserine in Psychotic Disorders. *Schizophrenia Bulletin*, **2017**, 43, S194-S195	1.3	1
282	Enhanced astrocytic d-serine underlies synaptic damage after traumatic brain injury. *Journal of Clinical Investigation*, **2017**, 127, 3114-3125	15.9	57
281	d-Serine and the Pathophysiology of Schizophrenia **2016**, 101-118		2

280	History of the Concept of Disconnectivity in Schizophrenia. *Harvard Review of Psychiatry*, **2016**, 24, 80-6	4.1	30
279	Touchscreen assays of learning, response inhibition, and motivation in the marmoset (Callithrix jacchus). *Animal Cognition*, **2016**, 19, 673-7	3.1	17
278	An mGlu5-Positive Allosteric Modulator Rescues the Neuroplasticity Deficits in a Genetic Model of NMDA Receptor Hypofunction in Schizophrenia. *Neuropsychopharmacology*, **2016**, 41, 2052-61	8.7	47
277	EphB3 signaling propagates synaptic dysfunction in the traumatic injured brain. *Neurobiology of Disease*, **2016**, 94, 73-84	7.5	16
276	Serine Racemase in Inhibitory Neurons at Striatum and it Might be Involved in Schizophrenia Pathophysiology with d1 and d2 Receptors. *European Psychiatry*, **2016**, 33, S467-S467	6	
275	My Life in Clinical Neuroscience: The Beginning. *Advances in Pharmacology*, **2016**, 76, 1-12	5.7	
274	The Rise and Fall of the d-Serine-Mediated Gliotransmission Hypothesis. *Trends in Neurosciences*, **2016**, 39, 712-721	13.3	110
273	Endogenous co-agonists of the NMDA receptor modulate contextual fear in trace conditioning. *Neurobiology of Learning and Memory*, **2016**, 136, 244-250	3.1	3
272	Possible compensatory mechanisms for glutamatergic disconnection found in the auditory cortex in schizophrenia. *Biological Psychiatry*, **2015**, 77, 923-4	7.9	1
271	Neuronal serine racemase regulates extracellular D-serine levels in the adult mouse hippocampus. *Journal of Neural Transmission*, **2015**, 122, 1099-103	4.3	22
270	Global biochemical profiling identifies 2-hydroxypyruvate as a potential mediator of type 2 diabetes in mice and humans. *Diabetes*, **2015**, 64, 1383-94	0.9	17
269	In vivo magnetic resonance studies reveal neuroanatomical and neurochemical abnormalities in the serine racemase knockout mouse model of schizophrenia. *Neurobiology of Disease*, **2015**, 73, 269-74	7.5	24
268	Availability of N-Methyl-d-Aspartate Receptor Coagonists Affects Cocaine-Induced Conditioned Place Preference and Locomotor Sensitization: Implications for Comorbid Schizophrenia and Substance Abuse. *Journal of Pharmacology and Experimental Therapeutics*, **2015**, 353, 465-70	4.7	10
267	Altered prefrontal cortical MARCKS and PPP1R9A mRNA expression in schizophrenia and bipolar disorder. *Schizophrenia Research*, **2015**, 164, 100-8	3.6	18
266	Subchronic pharmacological and chronic genetic NMDA receptor hypofunction differentially regulate the Akt signaling pathway and Arc expression in juvenile and adult mice. *Schizophrenia Research*, **2015**, 162, 216-21	3.6	10
265	The NMDA receptor glycine modulatory site in schizophrenia: D-serine, glycine, and beyond. *Current Opinion in Pharmacology*, **2015**, 20, 109-15	5.1	142
264	Prefrontal cortical dendritic spine pathology in schizophrenia and bipolar disorder. *JAMA Psychiatry* , **2014**, 71, 1323-31	14.5	217
263	D-serine deficiency attenuates the behavioral and cellular effects induced by the hallucinogenic 5-HT(2A) receptor agonist DOI. *Behavioural Brain Research*, **2014**, 259, 242-6	3.4	7

262	Chronic D-serine reverses arc expression and partially rescues dendritic abnormalities in a mouse model of NMDA receptor hypofunction. *Neurochemistry International*, **2014**, 75, 76-8	4.4	30
261	D-serine and serine racemase are localized to neurons in the adult mouse and human forebrain. *Cellular and Molecular Neurobiology*, **2014**, 34, 419-35	4.6	91
260	Time-dependent effects of haloperidol on glutamine and GABA homeostasis and astrocyte activity in the rat brain. *Psychopharmacology*, **2013**, 230, 57-67	4.7	10
259	Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, E2400-9	11.5	149
258	Glutamate Carboxypeptidase II **2013**, 1620-1627		5
257	Brain structural alterations induced by fetal exposure to cocaine persist into adolescence and affect behavior. *JAMA Psychiatry*, **2013**, 70, 1113-4	14.5	2
256	Identity of endogenous NMDAR glycine site agonist in amygdala is determined by synaptic activity level. *Nature Communications*, **2013**, 4, 1760	17.4	61
255	Relapse in alcohol use disorder--reply. *JAMA Psychiatry*, **2013**, 70, 1248	14.5	
254	The NMDA receptor co-agonists, D-serine and glycine, regulate neuronal dendritic architecture in the somatosensory cortex. *Neurobiology of Disease*, **2012**, 45, 671-82	7.5	73
253	NMDA receptor and schizophrenia: a brief history. *Schizophrenia Bulletin*, **2012**, 38, 920-6	1.3	274
252	Neuronal D-serine regulates dendritic architecture in the somatosensory cortex. *Neuroscience Letters*, **2012**, 517, 77-81	3.3	39
251	Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function. *Nature Chemical Biology*, **2012**, 8, 920-5	11.7	84
250	Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications. *Handbook of Experimental Pharmacology*, **2012**, 267-95	3.2	130
249	The JAMA Network Journals: New Names for the Archives Journals. *Archives of Neurology*, **2012**, 69, 817		
248	The Neurochemistry of Schizophrenia **2012**, 1000-1011		
247	Cell selective conditional null mutations of serine racemase demonstrate a predominate localization in cortical glutamatergic neurons. *Cellular and Molecular Neurobiology*, **2012**, 32, 613-24	4.6	113
246	Glutamate carboxypeptidase II and folate deficiencies result in reciprocal protection against cognitive and social deficits in mice: implications for neurodevelopmental disorders. *Developmental Neurobiology*, **2012**, 72, 891-905	3.2	15
245	NAAG, NMDA receptor and psychosis. *Current Medicinal Chemistry*, **2012**, 19, 1360-4	4.3	38

244	Altered acquisition and extinction of amphetamine-paired context conditioning in genetic mouse models of altered NMDA receptor function. *Neuropsychopharmacology*, **2012**, 37, 2496-504	8.7	15
243	Failure of NMDA receptor hypofunction to induce a pathological reduction in PV-positive GABAergic cell markers. *Neuroscience Letters*, **2011**, 488, 267-71	3.3	27
242	Serine racemase deletion disrupts memory for order and alters cortical dendritic morphology. *Genes, Brain and Behavior*, **2011**, 10, 210-22	3.6	92
241	Serine racemase deletion abolishes light-evoked NMDA receptor currents in retinal ganglion cells. *Journal of Physiology*, **2011**, 589, 5997-6006	3.9	19
240	Glutamate receptor composition of the post-synaptic density is altered in genetic mouse models of NMDA receptor hypo- and hyperfunction. *Brain Research*, **2011**, 1392, 1-7	3.7	28
239	Discordant behavioral effects of psychotomimetic drugs in mice with altered NMDA receptor function. *Psychopharmacology*, **2011**, 213, 143-53	4.7	12
238	Neuroplasticity signaling pathways linked to the pathophysiology of schizophrenia. *Neuroscience and Biobehavioral Reviews*, **2011**, 35, 848-70	9	123
237	Serine racemase deletion protects against cerebral ischemia and excitotoxicity. *Journal of Neuroscience*, **2010**, 30, 1413-6	6.6	84
236	Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia. *Dialogues in Clinical Neuroscience*, **2010**, 12, 359-82	5.7	53
235	MicroRNAs suggest a new mechanism for altered brain gene expression in schizophrenia. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 2975-6	11.5	26
234	Phenotypic characterization of mice heterozygous for a null mutation of glutamate carboxypeptidase II. *Synapse*, **2009**, 63, 625-35	2.4	22
233	The role of animal models in evaluating reasonable safety and efficacy for human trials of cell-based interventions for neurologic conditions. *Journal of Cerebral Blood Flow and Metabolism*, **2009**, 29, 1-9	7.3	32
232	Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior. *Molecular Psychiatry*, **2009**, 14, 719-27	15.1	244
231	The glycine transporter GlyT1 controls N-methyl-D-aspartic acid receptor coagonist occupancy in the mouse retina. *European Journal of Neuroscience*, **2009**, 30, 2308-17	3.5	17
230	Localization of NAAG-related gene expression deficits to the anterior hippocampus in schizophrenia. *Schizophrenia Research*, **2009**, 111, 131-7	3.6	29
229	Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. *Trends in Neurosciences*, **2008**, 31, 234-42	13.3	765
228	Science and Psychiatry: Groundbreaking Discoveries in Molecular Neuroscienceby Solomon H. Snyder, M.D. Arlington, Va, American Psychiatric Publishing, 2008, 513 pp., $65.00.. *American Journal of Psychiatry*, **2008**, 165, 1492-1493	11.9	
227	Psychiatric Neuroscience: Incorporating Pathophysiology into Clinical Case Formulation **2008**, 543-564		1

226	Modeling of context-dependent retrieval in hippocampal region CA1: implications for cognitive function in schizophrenia. *Schizophrenia Research*, **2007**, 89, 177-90	3.6	34
225	Low cerebrospinal fluid glutamate and glycine in refractory affective disorder. *Biological Psychiatry*, **2007**, 61, 162-6	7.9	117
224	Beyond in vitro data: a review of in vivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer's neuropathology. *Journal of Alzheimer's Disease*, **2007**, 11, 491-507	4.3	26
223	Endogenous N-acetylaspartylglutamate reduced NMDA receptor-dependent current neurotransmission in the CA1 area of the hippocampus. *Journal of Neurochemistry*, **2007**, 100, 346-57	6	34
222	Promoter analysis of human glutamate carboxypeptidase II. *Brain Research*, **2007**, 1170, 1-12	3.7	3
221	Ube3a mRNA and protein expression are not decreased in Mecp2R168X mutant mice. *Brain Research*, **2007**, 1180, 1-6	3.7	59
220	What can a clock mutation in mice tell us about bipolar disorder?. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 6097-8	11.5	14
219	Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms. *Neurotoxicity Research*, **2006**, 10, 221-33	4.3	64
218	Glial metabolites of tryptophan and excitotoxicity: coming unglued. *Experimental Neurology*, **2006**, 197, 4-7	5.7	12
217	Neurobiology of schizophrenia. *Neuron*, **2006**, 52, 139-53	13.9	526
216	Glutamate and schizophrenia: beyond the dopamine hypothesis. *Cellular and Molecular Neurobiology*, **2006**, 26, 365-84	4.6	658
215	A brief overview of N-acetylaspartate and N-acetylaspartylglutamate. *Advances in Experimental Medicine and Biology*, **2006**, 576, 1-6; discussion 361-3	3.6	1
214	NAAG reduces NMDA receptor current in CA1 hippocampal pyramidal neurons of acute slices and dissociated neurons. *Neuropsychopharmacology*, **2005**, 30, 7-16	8.7	60
213	Reduced glycine transporter type 1 expression leads to major changes in glutamatergic neurotransmission of CA1 hippocampal neurones in mice. *Journal of Physiology*, **2005**, 563, 777-93	3.9	38
212	Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of D-cycloserine. *Psychiatry Research - Neuroimaging*, **2005**, 138, 23-31	2.9	41
211	Do maternal folate and homocysteine levels play a role in neurodevelopmental processes that increase risk for schizophrenia?. *Harvard Review of Psychiatry*, **2005**, 13, 197-205	4.1	55
210	Ethics: Moral issues of human-non-human primate neural grafting. *Science*, **2005**, 309, 385-6	33.3	71
209	Folate, homocysteine, and negative symptoms in schizophrenia. *American Journal of Psychiatry*, **2004**, 161, 1705-8	11.9	105

208	Gene knockout of glycine transporter 1: characterization of the behavioral phenotype. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 8485-90	11.5	173
207	NMDA receptor function, neuroplasticity, and the pathophysiology of schizophrenia. *International Review of Neurobiology*, **2004**, 59, 491-515	4.4	104
206	Glutamate carboxypeptidase II gene expression in the human frontal and temporal lobe in schizophrenia. *Neuropsychopharmacology*, **2004**, 29, 117-25	8.7	38
205	Decoding schizophrenia. *Scientific American*, **2004**, 290, 48-55	0.5	20
204	The GABA-glutamate connection in schizophrenia: which is the proximate cause?. *Biochemical Pharmacology*, **2004**, 68, 1507-14	6	156
203	The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. *Psychopharmacology*, **2004**, 174, 32-8	4.7	172
202	Glutamate carboxypeptidase II **2004**, 960-963		
201	Regulation of glutamate carboxypeptidase II function in corticolimbic regions of rat brain by phencyclidine, haloperidol, and clozapine. *Neuropsychopharmacology*, **2003**, 28, 1227-34	8.7	23
200	Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. *Annals of the New York Academy of Sciences*, **2003**, 1003, 318-27	6.5	356
199	Early embryonic death of glutamate carboxypeptidase II (NAALADase) homozygous mutants. *Synapse*, **2003**, 50, 285-92	2.4	21
198	Finding the intracellular signaling pathways affected by mood disorder treatments. *Neuron*, **2003**, 38, 157-60	13.9	321
197	Use it or lose it--do effortful mental activities protect against dementia?. *New England Journal of Medicine*, **2003**, 348, 2489-90	59.2	58
196	L-type calcium channels reduce ROS generation in cerebellar granule cells following kainate exposure. *Synapse*, **2002**, 43, 30-41	2.4	11
195	Glutamatergic mechanisms in schizophrenia. *Annual Review of Pharmacology and Toxicology*, **2002**, 42, 165-79	17.9	515
194	Treating a child with Asperger's disorder and comorbid bipolar disorder. *American Journal of Psychiatry*, **2002**, 159, 13-21	11.9	39
193	Ionotropic glutamate receptors as therapeutic targets in schizophrenia. *CNS and Neurological Disorders*, **2002**, 1, 183-9		91
192	Chapter 1: Same brain, new decade: Challenges in CNS drug discovery in the postgenomic, proteomic era. *Annual Reports in Medicinal Chemistry*, **2001**, 36, 1-10	1.6	9
191	Drug treatment of anxiety disorders in children. *New England Journal of Medicine*, **2001**, 344, 1326-7	59.2	14

190	The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. *American Journal of Psychiatry*, **2001**, 158, 1367-77	11.9	745
189	Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimerß disease. *Biological Psychiatry*, **2001**, 49, 289-99	7.9	206
188	Insulin-like growth factor I prevents the development of sensitivity to kainate neurotoxicity in cerebellar granule cells. *Journal of Neurochemistry*, **2000**, 75, 1548-56	6	12
187	Detection of the effects of dopamine receptor supersensitivity using pharmacological MRI and correlations with PET. *Synapse*, **2000**, 36, 57-65	2.4	74
186	Intracellular modulation of NMDA receptor function by antipsychotic drugs. *Journal of Neuroscience* , **2000**, 20, 4011-20	6.6	128
185	Mind glue: implications of glial cell biology for psychiatry. *Archives of General Psychiatry*, **2000**, 57, 90-3		95
184	Psychotropic drug use in very young children. *JAMA - Journal of the American Medical Association*, **2000**, 283, 1059-60	27.4	62
183	Short-term and long-term effects of N-methyl-D-aspartate receptor hypofunction. *Archives of General Psychiatry*, **2000**, 57, 1180-1; author reply 1182-3		10
182	Ice-nine and human prion disease. *Harvard Review of Psychiatry*, **1999**, 6, 331-3	4.1	1
181	Site-directed mutagenesis of predicted active site residues in glutamate carboxypeptidase II. *Molecular Pharmacology*, **1999**, 55, 179-85	4.3	51
180	L-type voltage-gated calcium channels modulate kainic acid neurotoxicity in cerebellar granule cells. *Brain Research*, **1999**, 828, 27-40	3.7	34
179	Glutamate carboxypeptidase II is expressed by astrocytes in the adult rat nervous system. *Journal of Comparative Neurology*, **1999**, 415, 52-64	3.4	89
178	A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. *Archives of General Psychiatry*, **1999**, 56, 21-7		349
177	Effects of over- and under-expression of Cu,Zn-superoxide dismutase on the toxicity of glutamate analogs in transgenic mouse striatum. *Brain Research*, **1998**, 789, 32-9	3.7	49
176	Hydrolysis of the neuropeptide N-acetylaspartylglutamate (NAAG) by cloned human glutamate carboxypeptidase II. *Brain Research*, **1998**, 795, 341-8	3.7	42
175	Effects of overexpression of the cytoplasmic copper-zinc superoxide dismutase on the survival of neurons in vitro. *Synapse*, **1998**, 29, 206-12	2.4	11
174	Somatostatin expression in TS16 mouse brain cultures. *Journal of Molecular Neuroscience*, **1998**, 10, 99-111	3.3	2
173	Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia. *Biological Psychiatry*, **1998**, 44, 667-74	7.9	62

172	D-serine added to antipsychotics for the treatment of schizophrenia. *Biological Psychiatry*, **1998**, 44, 1081-9	7.9	539
171	The role of glutamatergic neurotransmission in the pathophysiology of alcoholism. *Annual Review of Medicine*, **1998**, 49, 173-84	17.4	325
170	Folylpoly-gamma-glutamate carboxypeptidase from pig jejunum. Molecular characterization and relation to glutamate carboxypeptidase II. *Journal of Biological Chemistry*, **1998**, 273, 20417-24	5.4	80
169	Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. *American Journal of Psychiatry*, **1998**, 155, 1207-13	11.9	201
168	The nagging question of the function of N-acetylaspartylglutamate. *Neurobiology of Disease*, **1997**, 4, 231-8	7.5	147
167	N-acetylaspartylglutamate (NAAG) protects against rat striatal quinolinic acid lesions in vivo. *Neuroscience Letters*, **1997**, 236, 91-4	3.3	33
166	Distribution of N-acetylaspartylglutamate immunoreactivity in human brain and its alteration in neurodegenerative disease. *Brain Research*, **1997**, 772, 9-22	3.7	41
165	N-acetylaspartylglutamate, N-acetylaspartate, and N-acetylated alpha-linked acidic dipeptidase in human brain and their alterations in Huntington and Alzheimer's diseases. *Molecular and Chemical Neuropathology*, **1997**, 31, 97-118		56
164	The glutamatergic dysfunction hypothesis for schizophrenia. *Harvard Review of Psychiatry*, **1996**, 3, 241-53	4.1	440
163	Mice transgenic for copper/zinc superoxide dismutase exhibit increased markers of biogenic amine function. *Journal of Neurochemistry*, **1995**, 65, 660-9	6	3
162	N-acetylated alpha-linked acidic dipeptidase is expressed by non-myelinating Schwann cells in the peripheral nervous system. *Journal of Neurocytology*, **1995**, 24, 99-109		48
161	Food for thought. *Nature Medicine*, **1995**, 1, 1006-7	50.5	
160	N-acetylaspartate in neuropsychiatric disorders. *Progress in Neurobiology*, **1995**, 46, 531-40	10.9	352
159	The neuroscience perspective and the changing role of the psychiatrist : the challenge for psychiatric educators. *Academic Psychiatry*, **1995**, 19, 202-12	1.1	5
158	Funding of NIMH extramural research. *Science*, **1994**, 264, 1517	33.3	
157	Cholinergic innervation of mouse forebrain structures. *Journal of Comparative Neurology*, **1994**, 341, 117-29	3.4	84
156	Developmental regulation of adult cortical morphology and behavior: an animal model for mental retardation. *International Journal of Developmental Neuroscience*, **1994**, 12, 239-53	2.7	38
155	Abnormal acidic amino acids and N-acetylaspartylglutamate in hereditary canine motoneuron disease. *Brain Research*, **1993**, 629, 305-9	3.7	13

154	Immunocytochemical distribution of N-acetylaspartylglutamate in the rat forebrain and glutamatergic pathways. *Journal of Chemical Neuroanatomy*, **1993**, 6, 277-92	3.2	28
153	Oxidative stress, glutamate, and neurodegenerative disorders. *Science*, **1993**, 262, 689-95	33.3	3346
152	Kainic acid-induced lipid peroxidation: protection with butylated hydroxytoluene and U78517F in primary cultures of cerebellar granule cells. *Brain Research*, **1993**, 624, 223-32	3.7	98
151	Dissociation of nitric oxide generation and kainate-mediated neuronal degeneration in primary cultures of rat cerebellar granule cells. *Neuropharmacology*, **1992**, 31, 565-75	5.5	43
150	Genetically epilepsy-prone rats have increased brain regional activity of an enzyme which liberates glutamate from N-acetyl-aspartyl-glutamate. *Brain Research*, **1992**, 593, 140-3	3.7	36
149	Brain serotonin2 and serotonin1A receptors are altered in the congenitally hyperammonemic sparse fur mouse. *Journal of Neurochemistry*, **1992**, 58, 1016-22	6	37
148	Immunocytochemical localization of the N-acetyl-aspartyl-glutamate (NAAG) hydrolyzing enzyme N-acetylated alpha-linked acidic dipeptidase (NAALADase). *Journal of Comparative Neurology*, **1992**, 315, 217-29	3.4	88
147	Kindling increases brain levels of NAAG and seizures reduce activity of a NAAG-hydrolyzing enzyme, NAALADase. *Epilepsy Research Supplement*, **1992**, 8, 297-305		2
146	Enhanced NAD(P)H:quinone reductase activity prevents glutamate toxicity produced by oxidative stress. *Journal of Neurochemistry*, **1991**, 56, 990-5	6	71
145	Excitatory amino acids in amyotrophic lateral sclerosis: an update. *Annals of Neurology*, **1991**, 30, 224-5	9.4	85
144	Developmental expression of the gene encoding growth-associated protein 43 (Gap43) in the brains of normal and aneuploid mice. *Journal of Neuroscience Research*, **1991**, 29, 449-60	4.4	11
143	Platelet serotonin, a possible marker for familial autism. *Journal of Autism and Developmental Disorders*, **1991**, 21, 51-9	4.6	114
142	Glutamate neurotoxicity and the inhibition of protein synthesis in the hippocampal slice. *Journal of Neurochemistry*, **1991**, 56, 996-1006	6	66
141	The potential for muscarinic receptor subtype-specific pharmacotherapy for Alzheimer's disease. *Mayo Clinic Proceedings*, **1991**, 66, 1225-37	6.4	73
140	Reductions in acidic amino acids and N-acetylaspartylglutamate in amyotrophic lateral sclerosis CNS. *Brain Research*, **1991**, 556, 151-6	3.7	96
139	Enhancement of NMDA receptor-mediated neurotoxicity in the hippocampal slice by depolarization and ischemia. *Brain Research*, **1991**, 555, 99-106	3.7	40
138	Effects of calmodulin antagonists on sodium-dependent high-affinity choline uptake. *Brain Research*, **1991**, 542, 132-4	3.7	7
137	In Reply: Neuroleptic Malignant Syndrome. *Pediatrics*, **1991**, 88, 1074-1074	7.4	3

136	Effects of different doses of galanthamine, a long-acting acetylcholinesterase inhibitor, on memory in mice. *Psychopharmacology*, **1990**, 102, 191-200	4.7	63
135	Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. *Annals of Neurology*, **1990**, 28, 18-25	9.4	541
134	Immature cortical neurons are uniquely sensitive to glutamate toxicity by inhibition of cystine uptake. *FASEB Journal*, **1990**, 4, 1624-1633	0.9	364
133	Increased number of somatostatin-immunoreactive neurons in primary cultures of trisomy 16 mouse neocortex. *Molecular Brain Research*, **1990**, 7, 269-72		11
132	Transplantation of brain tissue from murine trisomy 16 into euploid hosts: effects of gene imbalance on brain development. *Progress in Brain Research*, **1990**, 82, 203-14	2.9	9
131	Developmental expression of somatostatin in mouse brain. I. Immunocytochemical studies. *Developmental Brain Research*, **1990**, 53, 6-25		51
130	Developmental expression of somatostatin in mouse brain. II. In situ hybridization. *Developmental Brain Research*, **1990**, 53, 26-39		55
129	Galanthamine, an acetylcholinesterase inhibitor: a time course of the effects on performance and neurochemical parameters in mice. *Pharmacology Biochemistry and Behavior*, **1989**, 34, 129-37	3.9	56
128	Lesions of the basal forebrain alter stimulus-evoked metabolic activity in mouse somatosensory cortex. *Journal of Comparative Neurology*, **1989**, 288, 414-27	3.4	32
127	The postnatal expression of acetylcholinesterase in somatostatin-positive cells of mouse hippocampus. *Developmental Brain Research*, **1989**, 48, 73-85		10
126	Arachidonic Acid Metabolism in Glutamate Neurotoxicity. *Annals of the New York Academy of Sciences*, **1989**, 559, 474-477	6.5	22
125	Seizures decrease regional enzymatic hydrolysis of N-acetyl-aspartylglutamate in rat brain. *Brain Research*, **1989**, 505, 130-4	3.7	20
124	Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress. *Neuron*, **1989**, 2, 1547-58	13.9	822
123	The effects of N-acetylated alpha-linked acidic dipeptidase (NAALADase) inhibitors on [3H]NAAG catabolism in vivo. *Neuroscience Letters*, **1989**, 100, 295-300	3.3	45
122	Development of beta 1 and beta 2 adrenergic receptors in baboon brain: an autoradiographic study using [125I]iodocyanopindolol. *Journal of Comparative Neurology*, **1988**, 273, 318-29	3.4	23
121	Calcium-dependent evoked release of N-[3H]acetylaspartylglutamate from the optic pathway. *Journal of Neurochemistry*, **1988**, 51, 1956-9	6	64
120	Solubilization and characterization of a [3H]hemicholinium-3 binding site in rat brain. *Journal of Neurochemistry*, **1988**, 50, 1759-64	6	22
119	Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate: subcellular and regional distribution, ontogeny, and the effect of lesions on N-acetylated-alpha-linked acidic dipeptidase activity. *Journal of Neurochemistry*, **1988**, 50, 1200-9	6	72

118	A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice. *Pharmacology Biochemistry and Behavior*, **1988**, 31, 141-7	3.9	70
117	A re-examination of the interaction of N-acetyl-L-aspartyl-L-glutamate with a subpopulation of rat brain membrane L-[3H]glutamate binding sites. *European Journal of Pharmacology*, **1988**, 151, 419-26	5.3	13
116	Involvement of phospholipase A2 in the regulation of [3H]hemicholinium-3 binding. *Biochemical Pharmacology*, **1988**, 37, 4367-73	6	19
115	Calcium-dependent glutamate cytotoxicity in a neuronal cell line. *Brain Research*, **1988**, 444, 325-32	3.7	72
114	The role of calcium in the regulation of [3H]hemicholinium-3 binding sites in rat brain. *Neuropharmacology*, **1988**, 27, 1301-8	5.5	19
113	Down syndrome, Alzheimer's disease and the trisomy 16 mouse. *Trends in Neurosciences*, **1988**, 11, 390-4	13.3	80
112	Quantitation of N-acetyl-aspartyl-glutamate in microdissected rat brain nuclei and peripheral tissues: findings with a novel liquid phase radioimmunoassay. *Molecular Brain Research*, **1988**, 427, 223-31		34
111	Long-term effects of basal forebrain lesions on cholinergic, noradrenergic and serotonergic markers in mouse neocortex. *Brain Research Bulletin*, **1988**, 21, 13-20	3.9	18
110	Cerebrospinal fluid correlates of depression in Huntington's disease. *Archives of Neurology*, **1988**, 45, 881-3		28
109	Effect of sodium benzoate and sodium phenylacetate on brain serotonin turnover in the ornithine transcarbamylase-deficient sparse-fur mouse. *Pediatric Research*, **1988**, 23, 368-74	3.2	30
108	The Neurobiology of N-Acetylasparty. *International Review of Neurobiology*, **1988**, 39-100	4.4	67
107	Inhibition of [3H]kainic acid receptor binding by divalent cations correlates with ion affinity for the calcium channel. *Neuropharmacology*, **1987**, 26, 1247-51	5.5	107
106	Selective immunocytochemical staining of mitral cells in rat olfactory bulb with affinity purified antibodies against N-acetyl-aspartyl-glutamate. *Brain Research*, **1987**, 402, 373-8	3.7	60
105	The development of daytime rearing behavior in methylazoxymethanol-treated rats: methodological considerations. *Behavioural Brain Research*, **1987**, 25, 97-100	3.4	4
104	Age-related recurrence of basal forebrain lesion-induced cholinergic deficits. *Neuroscience Letters*, **1987**, 82, 253-9	3.3	41
103	Specific alterations in the levels of N-acetyl-aspartyl-glutamate in the nervous system of the dystrophic mouse. *Neuroscience Letters*, **1987**, 79, 223-8	3.3	12
102	Glutamate and related acidic excitatory neurotransmitters: from basic science to clinical application. *FASEB Journal*, **1987**, 1, 446-55	0.9	169
101	Co-localization of N-acetyl-aspartyl-glutamate in central cholinergic, noradrenergic, and serotonergic neurons. *Synapse*, **1987**, 1, 455-60	2.4	89

100	Developmental consequences of autosomal aneuploidy in mammals. *Genesis*, **1987**, 8, 249-65		25
99	Neurochemical characterization of embryonic brain development in trisomy 19 (Ts19) mice: implications of selective deficits observed for abnormal neural development in aneuploidy. *Genesis*, **1987**, 8, 267-79		17
98	Kainic acid: insights into excitatory mechanisms causing selective neuronal degeneration. *Novartis Foundation Symposium*, **1987**, 126, 186-203		20
97	Synaptosomal transport of radiolabel from N-acetyl-aspartyl-[3H]glutamate suggests a mechanism of inactivation of an excitatory neuropeptide. *Journal of Neurochemistry*, **1986**, 47, 1013-9	6	40
96	Suspected adverse methylphenidate-imipramine interactions in children. *Journal of Developmental and Behavioral Pediatrics*, **1986**, 7, 265-7	2.4	29
95	Cortical degeneration with swollen chromatolytic neurons: its relationship to Pick disease. *Journal of Neuropathology and Experimental Neurology*, **1986**, 45, 268-84	3.1	65
94	Topography of Locomotor Behaviour in the Chick. *Bird Behavior*, **1986**, 6, 93-96		1
93	Behavioral and neurotransmitter changes in the urease-infused rat: a model of congenital hyperammonemia. *Pediatric Research*, **1986**, 20, 1310-5	3.2	34
92	Quisqualate selectively inhibits a brain peptidase which cleaves N-acetyl-L-aspartyl-L-glutamate in vitro. *European Journal of Pharmacology*, **1986**, 130, 345-7	5.3	39
91	Basal forebrain neurons provide major cholinergic innervation of primate neocortex. *Neuroscience Letters*, **1986**, 66, 215-20	3.3	44
90	Rapid regulation of [3H]hemicholinium-3 binding sites in the rat brain. *Brain Research*, **1986**, 381, 191-4	3.7	55
89	Nicotinic acetylcholine binding sites in Alzheimer disease. *Brain Research*, **1986**, 371, 146-51	3.7	510
88	Anatomical predictors of behavioral recovery following fetal striatal transplants. *Brain Research*, **1986**, 365, 249-58	3.7	121
87	Anorexia and altered serotonin metabolism in a patient with argininosuccinic aciduria. *Journal of Pediatrics*, **1986**, 108, 705-9	3.6	36
86	Primary degenerative dementia without Alzheimer pathology. *Canadian Journal of Neurological Sciences*, **1986**, 13, 462-70	1	64
85	Cerebrospinal fluid acetylcholinesterase activity in senile dementia of the Alzheimer type. *Annals of Neurology*, **1985**, 17, 46-8	9.4	63
84	Dipeptides of glutamate and aspartate may be endogenous neuroexcitants in the rat hippocampal slice. *Journal of Neuroscience*, **1985**, 5, 1429-33	6.6	74
83	Basal forebrain lesions produce a dissociation of trial-dependent and trial-independent memory performance. *Brain Research*, **1985**, 345, 315-21	3.7	104

82	Combined use of tricyclic antidepressants and neuroleptics in the management of terminally ill children: a report on three cases. *Journal of the American Academy of Child Psychiatry*, **1985**, 24, 487-9		5
81	Excitatory amino acid analogs evoke release of endogenous amino acids and acetyl choline from chick retina in vitro. *Vision Research*, **1985**, 25, 1375-86	2.1	28
80	Characterization of [3H]hemicholinium-3 binding associated with neuronal choline uptake sites in rat brain membranes. *Brain Research*, **1985**, 348, 321-30	3.7	93
79	Regional brain levels of N-acetyl-aspartyl-glutamate: the effect of kindled seizures. *Brain Research*, **1985**, 346, 392-6	3.7	29
78	Memory impairments following basal forebrain lesions. *Brain Research*, **1985**, 346, 8-14	3.7	244
77	N-acetyl-aspartyl-glutamate: regional levels in rat brain and the effects of brain lesions as determined by a new HPLC method. *Journal of Neurochemistry*, **1984**, 43, 1136-42	6	327
76	Decreased cortical glucose utilization after ibotenate lesion of the rat ventromedial globus pallidus. *Journal of Cerebral Blood Flow and Metabolism*, **1984**, 4, 381-90	7.3	71
75	Parametric influences on catalepsy. *Psychopharmacology*, **1984**, 82, 406-8	4.7	19
74	Serum neuroleptic concentrations and clinical response: a radioreceptor assay investigation of acutely psychotic patients. *Psychopharmacology*, **1984**, 82, 194-8	4.7	16
73	Investigating locomotion abnormalities in animal models of extrapyramidal disorders: A commentary. *Physiological Psychology*, **1984**, 12, 48-50		15
72	The dissociation of evoked release of [3H]-GABA and of endogenous GABA from chick retina in vitro. *Experimental Eye Research*, **1984**, 39, 299-305	3.7	17
71	Neurotransmitter specific alterations in dementing disorders: insights from animal models. *Journal of Psychiatric Research*, **1984**, 18, 501-12	5.2	12
70	Regional heterogeneity of choline acetyltransferase activity in primate neocortex. *Brain Research*, **1984**, 322, 361-4	3.7	51
69	Effects of intrastriatal injections of the cholinergic neurotoxin AF64A on spontaneous nocturnal locomotor behavior in the rat. *Brain Research*, **1984**, 299, 339-43	3.7	28
68	Synaptic neurochemical alterations associated with neuronal degeneration in an inherited cerebellar ataxia of Gordon Setters. *Journal of Neuropathology and Experimental Neurology*, **1984**, 43, 580-91	3.1	10
67	Topographic analysis of the innervation of the rat neocortex and hippocampus by the basal forebrain cholinergic system. *Journal of Comparative Neurology*, **1983**, 217, 103-21	3.4	425
66	Evoked release of aspartate and glutamate: disparities between prelabeling and direct measurement. *Brain Research*, **1983**, 278, 279-82	3.7	37
65	Alzheimerß disease: a disorder of cortical cholinergic innervation. *Science*, **1983**, 219, 1184-90	33.3	2801

64	Automated measurement of stereotypic behavior in rats.. *Behavioral Neuroscience*, **1983**, 97, 830-832	2.1	34
63	Synaptic chemistry associated with aberrant neuronal development in the reeler mouse. *Journal of Neurochemistry*, **1983**, 41, 874-81	6	16
62	Neuroleptic drug level monitoring in psychiatry: focus on radioreceptor assay techniques. *Therapeutic Drug Monitoring*, **1982**, 4, 59-64	3.2	18
61	The clinical use of antipsychotic medications. *Medical Clinics of North America*, **1982**, 66, 993-1009	7	6
60	Somatostatin is not co-localized in cholinergic neurons innervating the rat cerebral cortex-hippocampal formation. *Brain Research*, **1982**, 243, 169-72	3.7	62
59	Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. *Science*, **1982**, 215, 1237-9	33.3	3072
58	Cytotoxic lesions and the development of transmitter systems. *Trends in Neurosciences*, **1982**, 5, 153-156	13.3	59
57	Neurotoxic amino acids in human degenerative disorders. *Trends in Neurosciences*, **1982**, 5, 287-288	13.3	19
56	Dopaminergic dsyfunction in Tourette syndrome. *Annals of Neurology*, **1982**, 12, 361-6	9.4	165
55	Effects of kainic acid on high-energy metabolites in the mouse striatum. *Journal of Neurochemistry*, **1982**, 38, 196-203	6	45
54	Kainic acid stimulates excitatory amino acid neurotransmitter release at presynaptic receptors. *Nature*, **1982**, 298, 757-9	50.4	270
53	N-Methyl-D-aspartate acid: a convulsant with weak neurotoxic properties. *Neuroscience Letters*, **1981**, 24, 181-6	3.3	25
52	Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. *Annals of Neurology*, **1981**, 10, 122-6	9.4	1507
51	Effects of spinal transection on presynaptic markers for glutamatergic neurons in the rat. *Neurochemical Research*, **1981**, 6, 485-96	4.6	10
50	Acute extrapyramidal side effects: serum levels of neuroleptics and anticholinergics. *Psychopharmacology*, **1981**, 75, 9-15	4.7	73
49	Development of central neurotransmitter systems. *Novartis Foundation Symposium*, **1981**, 86, 251-70		9
48	Local and distant neuronal degeneration following intrastriatal injection of kainic acid. *Journal of Neuropathology and Experimental Neurology*, **1980**, 39, 245-64	3.1	90
47	Ontogeny of neurochemical markers for noradrenergic, GABAergic, and cholinergic neurons in neocortex lesioned with methylazoxymethanol acetate. *Journal of Neurochemistry*, **1980**, 34, 1429-41	6	107

46	Characterization of specific, high-affinity binding sites for L-[3H]glutamic acid in rat brain membranes. *Brain Research*, **1980**, 183, 421-33	3.7	101
45	The differential effect of right versus left hemispheric cerebral infarction on catecholamines and behavior in the rat. *Brain Research*, **1980**, 188, 63-78	3.7	169
44	Phylogenetic distribution of [3H]kainic acid receptor binding sites in neuronal tissue. *Brain Research* , **1980**, 192, 463-76	3.7	68
43	The development of catecholaminergic innervation in chick spinal cord. *Brain Research*, **1980**, 191, 417-28	3.7	24
42	Striatal opiate receptors: pre- and postsynaptic localization. *Life Sciences*, **1980**, 27, 1175-83	6.8	86
41	Kainic acid lesion of mouse striatum: effects on energy metabolites. *Life Sciences*, **1980**, 27, 2495-500	6.8	17
40	Head and trunk neural crest in vitro: autonomic neuron differentiation. *Developmental Biology*, **1980**, 77, 340-8	3.1	48
39	Noradrenergic innervation patterns in three regions of medial cortex: an immunofluorescence characterization. *Brain Research Bulletin*, **1979**, 4, 849-57	3.9	51
38	Lateralization of catecholaminergic and behavioral response to cerebral infarction in the rat. *Life Sciences*, **1979**, 24, 943-50	6.8	49
37	Histological and neurochemical effects of fetal treatment with methylazoxymethanol on rat neocortex in adulthood. *Brain Research*, **1979**, 170, 135-55	3.7	185
36	Rotational behaviour in rats with unilateral striatal kainic acid lesions: a behavioural model for studies on intact dopamine receptors. *Brain Research*, **1979**, 170, 485-95	3.7	111
35	Methylazoxymethanol treatment of fetal rats results in abnormally dense noradrenergic innervation of neocortex. *Science*, **1979**, 203, 369-71	33.3	76
34	Effects of cortical ablation on the neurotoxicity and receptor binding of kainic acid in striatum. *Journal of Neuroscience Research*, **1979**, 4, 383-98	4.4	99
33	Dopamine receptors localised on cerebral cortical afferents to rat corpus striatum. *Nature*, **1978**, 271, 766-8	50.4	381
32	Absence of a relationship between sympathetic neuronal activity and turnover of serum dopamine-beta-hydroxylase. *Naunyn-Schmiedebergs Archives of Pharmacology*, **1978**, 304, 231-6	3.4	14
31	In situ injection of kainic acid: a new method for selectively lesioning neural cell bodies while sparing axons of passage. *Journal of Comparative Neurology*, **1978**, 180, 301-23	3.4	495
30	The distribution and orientation of noradrenergic fibers in neocortex of the rat: an immunofluorescence study. *Journal of Comparative Neurology*, **1978**, 181, 17-39	3.4	222
29	Structure-activity relations for the neurotoxicity of kainic acid derivatives and glutamate analogues. *Neuropharmacology*, **1978**, 17, 145-51	5.5	166

28	Influence of cortico-striatal afferents on striatal kainic acid neurotoxicity. *Neuroscience Letters*, **1978**, 8, 303-10	3.3	209
27	Neuronal localization of specific brain phosphoproteins. *Brain Research*, **1978**, 156, 345-50	3.7	36
26	Alterations of muscarinic cholinergic receptors in the rat striatum after kainic acid injections. *Brain Research*, **1978**, 152, 620-5	3.7	36
25	Long-term sequelae of striatal kainate lesion. *Brain Research*, **1978**, 152, 626-32	3.7	77
24	Neuronal mapping with kainic acid. *Trends in Neurosciences*, **1978**, 1, 132-135	13.3	12
23	Pharmacological augmentation of acetylcholine levels in kainate-lesioned rat striatum. *Biochemical Pharmacology*, **1978**, 27, 2962-5	6	29
22	Major innervation of newborn rat cortex by monoaminergic neurons. *Science*, **1977**, 196, 444-7	33.3	159
21	Selective destruction of neurons by a transmitter agonist. *Science*, **1977**, 198, 71-2	33.3	185
20	Psychiatric drugs in medical practice. *Medical Clinics of North America*, **1977**, 61, 891-905	7	2
19	The immunohistochemical demonstration of noradrenergic neurons in the rat brain: The use of homologous antiserum to dopamine-beta-hydroxylase. *Neuroscience Letters*, **1977**, 4, 127-34	3.3	70
18	Neurochemical sequelae of kainate injections in corpus striatum and substantia nigra of the rat. *Life Sciences*, **1977**, 20, 431-6	6.8	131
17	Striatal lesions with kainic acid: neurochemical characteristics. *Brain Research*, **1977**, 127, 235-49	3.7	443
16	Inhibitors of GABA metabolism: implications for Huntington's disease. *Annals of Neurology*, **1977**, 2, 299-303	34	30
15	Biochemical aspects of neurotransmission in the developing brain. *International Review of Neurobiology*, **1977**, 20, 65-103	4.4	130
14	Adenylate cyclase activity in chick retina. *General Pharmacology*, **1976**, 7, 349-54		17
13	Neurochemical aspects of the ontogenesis of cholinergic neurons in the rat brain. *Brain Research*, **1976**, 118, 429-40	3.7	412
12	Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. *Nature*, **1976**, 263, 244-6	50.4	1160
11	Subcellular localization of dopamine beta-hydroxylase and endogenous norepinephrine in the rat hypothalamus. *Brain Research*, **1974**, 65, 475-87	3.7	40

10	Avoidance conditioning in different strains of rats: neurochemical correlates. *Psychopharmacology*, **1973**, 31, 25-34	4.7	35
9	Dopaminergic neurons in explants of substantia nigra in culture. *Journal of Neurobiology*, **1973**, 4, 461-70		29
8	Tyrosine hydroxylase in rat brain--cofactor requirements, regional and subcellular distribution. *Biochemical Pharmacology*, **1972**, 21, 1935-44	6	285
7	Rapid axonal transport of tyrosine hydroxylase and dopamine- -hydroxylase. *Brain Research*, **1972**, 44, 701-4	3.7	32
6	DOPA decarboxylase in the developing rat brain. *Brain Research*, **1972**, 41, 503-6	3.7	117
5	The role of brain dopamine in behavioral regulation and the actions of psychotropic drugs. *American Journal of Psychiatry*, **1970**, 127, 199-207	11.9	170
4	Uptake and Subcellular Localization of Neurotransmitters in the Brain. *International Review of Neurobiology*, **1970**, 13, 127-158	4.4	96
3	Section summary and perspectives: Translational medicine in psychiatry118-128		
2	The discovery and development of drugs to treat psychiatric disorders: Historical perspective1-13		
1	Glutamatergic Synaptic Dysregulation in Schizophrenia115-142		